All In Biotech

Drug Trial Radar · NCT00816023

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

CONSERV-1 (Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) A Phase 2 Randomized Placebo-controlled Dose-ranging Study in Subjects Exposed to Cardio-pulmonary Bypass During Primary Coronary Artery Bypass Graft Surgery

Last checked: Nov 20, 2026Latest source record: Aug 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

276

Actual

Start

Mar 2009

Primary completion

Dec 2009

Study completion Jan 2010

Sponsor

Sponsor type
Industry
First posted
Dec 31, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.

Conditions

  • Bloodloss
  • Surgical Procedures, Operative

Interventions

  • ecallantideDrug

    infusion administered IV over the duration of the surgical procedure

  • placeboDrug

    solution for IV infusion over the duration of the surgical\>\> procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Volume of Packed Red Blood Cells Transfused at 12 Hours Post SurgeryTime frame: Start of surgery up to 12 hours after the end of surgery

Locations

29 sites in 2 countries. Site status is shown where the registry gives one.

  • Cardio-Thoracic Surgeons PC

    Birmingham, Alabama

  • Drug Research and Analysis Corporation

    Montgomery, Alabama

  • University of Colorado - Denver

    Aurora, Colorado

  • Pepin Heart Hospital & Kiran Patel Research Institute

    Tampa, Florida

  • Indiana Ohio Heart

    Fort Wayne, Indiana

  • University of Kentucky

    Lexington, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Caritas St. Elizabeth's Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • MCVI - Covenant Medical Center

    Saginaw, Michigan

  • MCVI - St. Mary's of Michigan

    Saginaw, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • St. Luke's - Roosevelt Hospital Center

    New York, New York

  • Weill Medical College of Cornell University

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Integris Baptist Medical Center

    Oklahoma City, Oklahoma

  • East Tennessee Cardiovascular Surgery Group

    Knoxville, Tennessee

  • Texas Heart Institute

    Houston, Texas

  • Sentara Heart Hospital

    Norfolk, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • Charleston Area Medical Center (CAMC)

    Charleston, West Virginia

  • Foothills Medical Centre

    Calgary, Alberta, Canada

  • St. Boniface General Hospital

    Winnipeg, Manitoba, Canada

  • New Brunswick Heart Centre

    Saint John, New Brunswick, Canada

  • Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Montreal Heart Institute

    Montreal, Quebec, Canada

  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec (Hospital Laval)

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.